莎普愛思(603168.SH)旗下強身藥業獲得藥品GMP證書
格隆匯12月2日丨莎普愛思(603168.SH)公佈,近日,公司全資子公司莎普愛思強身藥業有限公司(“強身藥業”)收到吉林省藥品監督管理局頒發的《藥品GMP證書》
認證範圍:酒劑(酒劑車間二)(含中藥前處理及提取);有效期至2024年11月27日
此次認證車間為強身藥業酒劑車間二(含中藥前處理及提取)生產線;截至2019年9月底,上述生產線累計投入約9741.57萬元。
強身藥業酒劑車間二(含中藥前處理及提取)生產線通過GMP認證並獲發《藥品GMP證書》,表明強身藥業上述生產線符合GMP要求,有利於保持穩定的產品質量和充足的生產能力,更好地滿足市場需求。
此次強身藥業獲得《藥品GMP證書》不會對本公司當期業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.